(Q37409490)

20 August 2017

1 reference

title

Autoimmune myasthenia gravis (English)

1 reference

20 August 2017

0 references

1

Nils Erik Gilhus

1 reference

20 August 2017

publication date

1 March 2009

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

20 August 2017

published in

1 reference

20 August 2017

volume

9

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

351-358

1 reference

Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Ocular myasthenia: diagnostic and treatment recommendations and the evidence base

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Guidelines for the treatment of autoimmune neuromuscular transmission disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Titin and ryanodine receptor antibodies in myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Response to therapy in myasthenia gravis with anti-MuSK antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Immunosuppressive or surgical treatment for ocular Myasthenia Gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Ocular Myasthenia Gravis treatment: the case against prednisone therapy and thymectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Clinical evaluation and management of myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Treatment and clinical research in myasthenia gravis: how far have we come?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Lifetime course of myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Lessons from two trials of mycophenolate mofetil in myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Tacrolimus for myasthenia gravis: a clinical study of 212 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Myasthenia gravis: clinical, immunological, and therapeutic advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Optimal therapy for thymoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Artrogryposis multiplex congenita -- a rare fetal condition caused by maternal myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Genetic factors in autoimmune myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Treatment of myasthenia gravis by preventing acetylcholine receptor modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Antisense treatment for myasthenia gravis: experience with monarsen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.9.3.351

21 January 2018

Identifiers

DOI

10.1586/14737175.9.3.351

1 reference

20 August 2017

1 reference